Publications by authors named "M W P Bruysters"

The UK National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) is reviewing World Health Organization (WHO) manuals, guidelines and recommendations for vaccines and biotherapeutics to identify the extent to which animal-based testing methods are described. The aim is to recommend where updates to these documents can lead to an increased and more harmonised adoption of 3Rs principles (i.e.

View Article and Find Full Text PDF

Vaccines have been a key tool in stemming the tide of the COVID-19 pandemic. The rapid development of effective vaccines against COVID-19, together with their regulatory approval and wide scale distribution has been achieved in an impressively short period thanks to the intense efforts of many. In parallel to vaccine development, the EU considered it important to prepare for the independent control of the COVID-19 vaccines, including testing, to help ensure that only vaccines that comply with the approved quality requirements reach the public and to help improve/increase public confidence in the vaccines.

View Article and Find Full Text PDF

Within the Innovative Medicines Initiative 2 (IMI 2) project VAC2VAC (Vaccine batch to vaccine batch comparison by consistency testing), a workshop has been organised to discuss ways of improving the design of multi-centre validation studies and use the data generated for product-specific validation purposes. Moreover, aspects of validation within the consistency approach context were addressed. This report summarises the discussions and outlines the conclusions and recommendations agreed on by the workshop participants.

View Article and Find Full Text PDF

Safety and potency assessment for batch release testing of established vaccines still relies partly on animal tests. An important avenue to move to batch release without animal testing is the consistency approach. This approach is based on thorough characterization of the vaccine, and the principle that the quality of subsequent batches is the consequence of the application of consistent production of batches monitored by a GMP quality system.

View Article and Find Full Text PDF
Article Synopsis
  • Pertussis vaccines protect infants from whooping cough, but their main antigen, pertussis toxin (PT), lacks adequate safety testing.
  • The only accepted test, the histamine sensitization test, is an unreliable and lethal animal assay that may not fully capture PT's safety profile.
  • The authors developed an in vitro safety test using human cell lines to analyze PT's clinical effects, aiming to improve safety evaluations for vaccines and provide a model for other similar testing scenarios.
View Article and Find Full Text PDF